Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2003
10/15/2003EP1189627B1 Compositions containing soluble forms of hla-g for treating inflammatory skin pathologies
10/15/2003EP0796276B1 Gradual modification, super-agonists and antagonists of signal-proteins and peptides
10/15/2003EP0706568B1 Vertebrate apoptosis gene: compositions and methods
10/15/2003EP0585398B1 Hcv genomic sequences for diagnostics and therapeutics
10/15/2003CN1449446A Streptococcus antigens
10/15/2003CN1449445A Ev-vegf nucleic acids and polypeptides and methods of use
10/15/2003CN1449440A Masp-2, a complement-fixing enzyme, and uses for it
10/15/2003CN1449410A Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
10/15/2003CN1449407A Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acidor a glutamine in the form of physiologically acceptable
10/15/2003CN1449294A Parenteral vaccine formulations and uses thereof
10/15/2003CN1449293A Multivalent vaccine composition
10/15/2003CN1448509A Human ICAM-1 extramembranous I-III domain gene expression product ,its prep. and application in radioimmunological technology
10/15/2003CN1448420A Hydrophilic polymer and tanshinones medicine conjugation agent and medicine composition containing same
10/15/2003CN1448407A Production process of human immunoglobulin for intravenous injection
10/15/2003CN1448183A Tumour-curing specific target guiding administration system and use in preparation of tumour-curing medicine
10/15/2003CN1124284C High-effective broad-spectrum antibody for inhibiting growth and metastasis of tumour
10/15/2003CN1124159C Vaccines against aujeszky's disease and other animal diseases containing pseudorabies virus mutants
10/14/2003US6632928 Immunotoxins and methods of inducing immune tolerance
10/14/2003US6632926 Amino acids inserted in hypervariable region; heavy chain variable domain of an antibody that binds vascular endothelial growth factor
10/14/2003US6632923 Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis
10/14/2003US6632664 Foreign gene inserted into an untranslated region in the genome
10/14/2003US6632663 DNA immunization against chlamydia infection
10/14/2003US6632648 Methods of terminal sterilization of fibrinogen
10/14/2003US6632647 Use of strains of parapoxvirus ovis against organ fibrosis
10/14/2003US6632617 Tumor-associated antigen
10/14/2003US6632604 Nucleic acid sequences of CIITA genes which can be involved in controlling and regulating the expression of genes encoding MHC type II molecules, and their use, in particular as drugs
10/14/2003US6632459 For prophylaxis and therapy of diseases, infections
10/14/2003US6632441 Mutants of streptococcal toxin a and methods of use
10/14/2003US6632439 Fusobacterium necrophorum vaccine and method for making such vaccine
10/14/2003US6632438 Vaccines
10/14/2003US6632437 Immunogenic polysaccharide-protein conjugates containing poly α(2→8), α(2→9) NeuNAc capsular polysaccharides
10/14/2003US6632436 Administering a fusion protein of an antigen with an antigen presenting cell (APC) binding domain of an opsonin
10/14/2003US6632435 CTL epitope analogs
10/14/2003US6632434 Leptospiral major outer membrane protein, LipL 32
10/14/2003US6632433 Treating cholinergic controlled secretions including excess sweating, lacrimation and mucus secretion to reduce them; smooth muscle disorders; antispasmodic agents; analgesics; cardiovascular arterioles; gastrointestinal disorders
10/14/2003US6632432 Plasma from donors immunized with Staphylococcal epidermidis vaccine comprising antigens in TCA (trichloroacetic acid) extractions
10/14/2003US6632431 Anti-idiotypic antibody against FimH adhesion of uropathogenic type I-fimbriated Escherichia coli, compositions containing same and method for using same
10/14/2003CA2385777A1 Use of anti-tnf.alpha.antibodies and another drug
10/14/2003CA2085827C Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
10/14/2003CA2080018C Novel t-cell lymphoma cdna clones
10/09/2003WO2003083442A2 Life sciences business systems and methods
10/09/2003WO2003083135A2 Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 2 (npff2)
10/09/2003WO2003083115A1 Abc transporter-associated gene abcc13
10/09/2003WO2003083098A2 Nucleic acid sequence and protein in addition to polypeptides coding for mannitol-dehydrogenases or parts thereof and the production and use thereof in diagnosis and therapy
10/09/2003WO2003083095A1 Viral mutants, manipulated in the furin cleavage sites of glycoproteins
10/09/2003WO2003083083A2 Methods of using flt3-ligand in immunization protocols
10/09/2003WO2003083069A2 Activation of tumor-reactive lymphocytes via antibodies or genes recognizing cd3 or 4-1bb
10/09/2003WO2003083061A2 Anti-tnf antibodies, compositions, methods and uses
10/09/2003WO2003083058A2 Replikin peptides in rapid replication of glioma cells and in influenza epidemics
10/09/2003WO2003083041A2 Cripto-specific antibodies
10/09/2003WO2003083039A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/09/2003WO2003082916A2 Tumour associated antigens
10/09/2003WO2003082908A2 Use of the p17 protein of hiv in isolated form for the preparation of a medicament for administration to hiv seropositive patients, as well as pharmaceutical compositions comprising said protein
10/09/2003WO2003082897A2 Synthetic active peptide fragments
10/09/2003WO2003082809A1 Diaminoacid-aminoacid-polyamine based gemini surfactant compounds
10/09/2003WO2003082349A1 Treatment methods for eotaxin mediated inflammatory conditions
10/09/2003WO2003082348A1 Nanogel networks including polyion polymer fragments and biological agent compositions thereof
10/09/2003WO2003082345A1 Drugs comprising protein forming hollow nanoparticles and therapeutic substance to be transferred into cells fused therewith
10/09/2003WO2003082330A1 Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles
10/09/2003WO2003082328A1 Use of discoidin domain receptor 1 (ddr1) and agents that affect the ddr1/collagen pathway
10/09/2003WO2003082327A2 Combined dna/protein vaccine compositions
10/09/2003WO2003082316A1 Microgel particles for the delivery of bioactive materials
10/09/2003WO2003082314A2 Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
10/09/2003WO2003082269A1 Use of statins and other immunomodulatory agents in the treatment of autoimmune disease
10/09/2003WO2003082255A2 Use of mob-5 in pain
10/09/2003WO2003082212A2 Method for treating cancer in humans
10/09/2003WO2003082209A2 Cochleates made with purified soy phosphatidylserine
10/09/2003WO2003082183A2 Protein-based streptococcus pneumoniae vaccines
10/09/2003WO2003082011A1 Use of non-antibacterial tetracycline analogs and formulations thereof for the treatment of bacterial exotoxins
10/09/2003WO2003049667A3 The method of treating cancer
10/09/2003WO2003045466A3 Catheter composition and uses thereof
10/09/2003WO2003040170A3 Antibodies to cd40
10/09/2003WO2003037367A3 New bacterium causing poultry disease and vaccine derived thereof
10/09/2003WO2003034981A3 Prevention of recurrent viral disease
10/09/2003WO2003028661A3 Adjuvanted meningococcus compositions
10/09/2003WO2003022880A3 Synthetic hcv envelope proteins and their use for vaccination
10/09/2003WO2003020750A3 Antigen mimotopes and vaccine against cancers
10/09/2003WO2003007889A3 Therapeutic agents comprising pro-apoptotic proteins
10/09/2003WO2003006893A3 Methods of inhibiting amyloid toxicity
10/09/2003WO2003000878A3 Use of fkbp chaperones as expression tool
10/09/2003WO2002102828A3 Chimeric flavivirus vectors
10/09/2003WO2002092011A3 Methods of treating antibody-mediated pathologies using agents which inhibit cd21
10/09/2003WO2002092004A3 Use of hmg fragment as anti-inflammatory agents
10/09/2003WO2002067846A8 A vaccine composition and method of using the same
10/09/2003WO2002066629A3 Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates
10/09/2003WO2002060955A3 Modified antibodies and methods of use
10/09/2003WO2002059154A3 Neutralizing human monoclonal antibodies against hiv-1, their production and uses
10/09/2003WO2002056905A3 Molecular antigen array
10/09/2003WO2002040676A3 Mutant allergens
10/09/2003WO2002033099A3 Human kinases
10/09/2003WO2002022664A3 Antigenic proteins of shrimp white spot syndrome virus and uses thereof
10/09/2003WO2002016612A3 Genes and proteins, and their uses
10/09/2003WO2002010382A3 Trp8, trp9 and trp10, markers for cancer
10/09/2003US20030192067 Delivery system
10/09/2003US20030191286 Purification and characterization of soluble human HLA proteins
10/09/2003US20030191282 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/09/2003US20030191281 Of given amino acid sequence; culturing host cells transformed with vector
10/09/2003US20030191083 Screening, detection microbiocides; sepsis, rheumatic diseases, antiarthritic agents; bactericides
10/09/2003US20030191082 Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
10/09/2003US20030191079 Methods for treating and preventing infectious disease
1 ... 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 ... 1823